Shizuoka, Japan

Tomoya Kotake


 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Tomoya Kotake: Innovator in Cyclic Compounds

Introduction

Tomoya Kotake is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of cyclic compounds with selective inhibitory effects. His work has led to advancements in targeted therapies for various diseases.

Latest Patents

Tomoya Kotake holds 3 patents that showcase his innovative research. His latest patents include a cyclic compound having a selective KRAS inhibitory effect on HRAS and NRAS. This invention highlights the discovery of cyclic compounds that selectively inhibit KRAS, which interact with an amino acid residue specific to KRAS. Another notable patent is the spiroimidazolone derivative, which relates to a compound represented by a specific formula, or a pharmacologically acceptable salt thereof.

Career Highlights

Tomoya Kotake is associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at the company has been instrumental in advancing research and development in the field of pharmaceuticals. His innovative approach has contributed to the company's reputation for excellence in drug discovery.

Collaborations

Tomoya has collaborated with notable colleagues, including Toru Esaki and Yoshikazu Nishimura. These collaborations have fostered a productive research environment, leading to significant advancements in their respective fields.

Conclusion

Tomoya Kotake is a distinguished inventor whose work in cyclic compounds has the potential to impact therapeutic strategies significantly. His contributions to medicinal chemistry continue to pave the way for future innovations in drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…